Rising RSV burden across infants and older adults and next-generation biologics drive the market toward USD 2.4 billion by 2030.

Once overlooked, RSV is now gaining long-needed attention as innovation in monoclonal antibodies and antivirals reshapes prevention and treatment across age groups.”
— DataM Intelligence

AUSTIN, TX, UNITED STATES, December 19, 2025 /EINPresswire.com/ -- According to DataM Intelligence, the global respiratory syncytial virus therapeutics market was valued at approximately USD 1.2 billion in 2024 and is projected to reach around USD 2.4 billion by 2030. , expanding at a strong CAGR of about 10.2% during the forecast period. This rapid growth is driven by rising RSV incidence across all age groups, increasing awareness of RSV-related complications in older adults, and the introduction of next-generation monoclonal antibodies and antivirals with improved efficacy and longer duration of protection. Among therapeutic classes, monoclonal antibodies currently represent the leading segment due to their established clinical effectiveness, while North America dominates the global market owing to high diagnosis rates, strong reimbursement frameworks, and early adoption of novel RSV therapies.

?????? ?? ???????????? ?????? ???????????????? ???? ?????? ???????????? (?????? ?????????????????? ?????????? ???? ?????? ?? ?????????? ????????????????): https://www.datamintelligence.com/download-sample/respiratory-syncytial-virus-therapeutics-market

Respiratory Syncytial Virus (RSV) is one of the most common and serious causes of lower respiratory tract infections, particularly affecting infants, young children, older adults, and immunocompromised individuals. RSV infections can lead to severe conditions such as bronchiolitis and pneumonia, often resulting in hospitalization and, in high-risk populations, increased mortality. Despite its significant global disease burden, RSV remained an under-addressed therapeutic area for decades, with limited treatment options largely focused on supportive care and preventive monoclonal antibodies for high-risk infants. In recent years, however, scientific breakthroughs in virology, immunology, and biologics have reignited strong interest in the development of effective RSV therapeutics, positioning this market as one of the most dynamic segments within infectious disease treatment.

Key Highlights from the Report
? RSV therapeutics demand is rising due to increasing infection rates in infants and elderly populations.

? Monoclonal antibodies dominate the market with proven clinical efficacy.

? Antiviral drug development is accelerating with multiple candidates in late-stage pipelines.

? North America leads the market due to advanced healthcare systems and strong regulatory support.

? Europe follows with increasing focus on RSV prevention in aging populations.

? Asia-Pacific is expected to witness the fastest growth during the forecast period.

Market Segmentation
The respiratory syncytial virus therapeutics market is segmented based on drug class, indication, patient population, route of administration, and end-user, reflecting the complexity and evolving nature of RSV treatment strategies.

- By drug class, the market includes monoclonal antibodies, antiviral drugs, immunoglobulins, and supportive therapies. Monoclonal antibodies hold the largest share of the market, driven by their ability to provide targeted immune protection against RSV. These therapies are especially critical for preventing severe RSV infections in high-risk infants and are increasingly being evaluated for use in older adults. Antiviral drugs represent a rapidly growing segment, as pharmaceutical companies invest heavily in small-molecule antivirals designed to reduce viral replication and disease severity. Immunoglobulins and supportive therapies continue to play a role, particularly in severe cases requiring hospitalization.

- By indication, RSV therapeutics are primarily used for bronchiolitis, pneumonia, and other RSV-associated lower respiratory tract infections. Bronchiolitis remains the most common indication, particularly among infants and young children, driving consistent demand for effective RSV interventions. Pneumonia-related RSV cases, especially among elderly and immunocompromised patients, are gaining increased clinical attention, further expanding the therapeutic market.

- By patient population, the market is segmented into pediatric, adult, and geriatric patients. The pediatric segment accounts for the largest market share due to the high incidence of RSV infections in infants under one year of age. However, the geriatric segment is emerging as a key growth driver, as growing evidence highlights the severe impact of RSV on older adults, comparable to influenza in terms of hospitalization and mortality risk.

- By route of administration, RSV therapeutics are delivered through injectable, oral, and inhalation routes. Injectable therapies, particularly monoclonal antibodies, dominate the market due to their long-acting nature and high bioavailability. Oral and inhaled formulations are gaining traction as they offer improved patient convenience and potential for broader outpatient use.

- By end-user, the market serves hospitals, specialty clinics, and home healthcare settings. Hospitals represent the largest end-user segment, driven by the need for acute management of severe RSV infections. However, the expansion of preventive and long-acting therapies is gradually shifting some demand toward outpatient and home-based care settings.

Regional Insights
- North America holds the dominant position in the global RSV therapeutics market. The region benefits from high RSV awareness, widespread diagnostic testing, and strong government and private investments in infectious disease research. The United States, in particular, leads in terms of product approvals and clinical trials, supported by favorable reimbursement policies and rapid adoption of innovative biologics.

- Europe represents a significant share of the market, driven by increasing recognition of RSV as a major public health concern, especially among older adults. Countries such as Germany, the UK, France, and Italy are actively integrating RSV prevention strategies into national healthcare systems. Strong regulatory support and collaborative research initiatives across the region further support market growth.

- The Asia-Pacific region is expected to experience the fastest growth during the forecast period. Rising birth rates in certain countries, expanding elderly populations, and improving healthcare infrastructure are key factors driving demand. Countries such as China, Japan, India, and South Korea are investing in advanced diagnostics and therapeutics, while partnerships between global pharmaceutical companies and regional manufacturers are accelerating market penetration.

- Latin America and the Middle East & Africa are emerging markets with growing RSV disease awareness. Although limited access and affordability challenges currently restrict widespread adoption, increasing healthcare investments, expanding immunization programs, and international health initiatives are expected to gradually improve access to RSV therapeutics in these regions.

Market Dynamics
1) Market Drivers
One of the primary drivers of the RSV therapeutics market is the high global disease burden of RSV, particularly among infants and older adults. Increasing hospitalization rates and the lack of curative treatments have intensified the need for effective therapeutic and preventive options. Advances in biologics, improved understanding of RSV pathogenesis, and growing emphasis on preventive healthcare are further accelerating market growth. Additionally, regulatory agencies are providing fast-track and breakthrough designations to promising RSV therapies, encouraging innovation and investment.

2) Market Restraints
Despite strong growth prospects, the market faces challenges such as high treatment costs, particularly for monoclonal antibody therapies, which can limit access in low- and middle-income countries. Limited awareness of RSV severity in adults, lack of universal screening, and logistical challenges associated with injectable therapies also pose barriers to market expansion. Furthermore, seasonal variability in RSV outbreaks can create fluctuations in demand.

3) Market Opportunities
The RSV therapeutics market presents significant opportunities through the development of long-acting antibodies, oral antivirals, and combination therapies that can improve patient compliance and reduce healthcare burden. Expansion into adult and geriatric indications offers substantial untapped potential. Advances in vaccine-adjacent therapeutic strategies and increased public-private collaborations are also expected to open new growth avenues in the coming years.

Reasons to Buy the Report
? Gain in-depth insights into the global RSV therapeutics market landscape.
? Identify high-growth therapeutic classes and emerging drug candidates.
? Understand regional demand patterns and future growth opportunities.
? Analyze competitive strategies and pipeline developments of key players.
? Support strategic planning with reliable forecasts from DataM Intelligence.

Frequently Asked Questions (FAQs)
? How big is the global respiratory syncytial virus therapeutics market?
? Who are the key players in the global RSV therapeutics market?
? What is the projected growth rate of the respiratory syncytial virus therapeutics market?
? What is the market forecast for RSV therapeutics through 2031?
? Which region is estimated to dominate the RSV therapeutics industry during the forecast period?

Company Insights
Key players operating in the respiratory syncytial virus therapeutics market include:
• AstraZeneca
• Sanofi
• Pfizer Inc.
• Roche Holding AG
• GlaxoSmithKline plc
• Johnson & Johnson
• Moderna, Inc.
• AbbVie Inc.

Recent Developments
- In November 2025, AstraZeneca and Sanofi expanded global access programs for their long-acting monoclonal antibody therapy for RSV prevention in infants, supported by increased manufacturing capacity.

- In October 2025, Pfizer announced positive late-stage clinical trial results for an investigational RSV antiviral targeting adult and elderly populations, strengthening its infectious disease portfolio.

Conclusion
The respiratory syncytial virus therapeutics market is undergoing a profound transformation, driven by scientific innovation, heightened disease awareness, and expanding patient populations. Insights from DataM Intelligence underscore the strong growth potential of this market as new monoclonal antibodies and antivirals redefine RSV management across pediatric and adult populations. While challenges related to cost and access remain, continued advancements in drug development and supportive regulatory environments are expected to fuel sustained market expansion. As RSV gains recognition as a serious global health threat, therapeutics targeting this virus will play an increasingly vital role in improving patient outcomes and reducing healthcare burden worldwide.

Sai Kiran
DataM Intelligence 4market Research LLP
+1 877-441-4866
[email protected]
Visit us on social media:
LinkedIn
YouTube
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]